Introduction of the Related Content of Biotech Drugs Quality Control in the Chinese Pharmacopoeia 2015
RAO Chun-ming, WANG Jun-zhi*
National Institutes for Food and Drug Control,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,Beijing 100050,China
Abstract��The Chinese pharmacopoeia 2015 has been issued.To better understand and implement the new pharmacopoeia, this article first briefly reviews the situation of biotech drugs quality control after the execution of the 2010 edition pharmacopoeia, lists related issues, and illustrates the necessity to study and understand the new pharmacopoeia and related documents in time.Then according to the relevant regulations and the Chinese pharmacopoeia 2015 Volume ��, the contents of the draft of biotech drugs quality control are introduced, including research basis and regulations of quality standards, the general notice and related provisions of standard materials such as standard, reference, reference substance in the article 26 in the notice,general requirements and six requirements related to the production and quality control of biotech drugs,general monograph of human recombinant DNA technology products and general monograph of human recombinant monoclonal antibody products,the monograph and the China��s 2013 annual valuation to sample vial recombinant human interferon alpha 2a as an example analysis for verification regulation related content,and appendices and the second method (reporter gene method) for determination of interferon biological activity in the new appendix.The advantages and disadvantages of the requirements on products contained in this edition of pharmacopoeia were discussed, as well as the regulations and technical background when the quality standards were formulated.Focus was put on the importance of peptide mapping analysis in the structure analysis of recombinant protein product and the stability evaluation of production process, key technical requirements in new general monograph of human recombinant DNA technology products, and the application of new technologies, such as LC-MS in structure analysis of biotech drugs protein and identification of reference substance, etc.
�Ĵ���, ����־. 2015��桶�й�ҩ�䡷���＼��ҩ��������������ݽ���[J]. �й�ҩѧ��־, 2015, 50(20): 1776-1781.
RAO Chun-ming, WANG Jun-zhi. Introduction of the Related Content of Biotech Drugs Quality Control in the Chinese Pharmacopoeia 2015. Chinese Pharmaceutical Journal, 2015, 50(20): 1776-1781.
SFDA. Guidelines for Study of Human Recombinant DNA Product Quality Control(��������DNA��Ʒ�������Ƽ���ָ��ԭ��) [S]. 2003.
[3]
SFDA. Guidelines for Study of Human Monoclonal Antibody Quality Control(���õ���¡�����������Ƽ���ָ��ԭ��) [S]. 2003.
[4]
EP 7.0 [S]. 2011: 692-693.
[5]
USP 34 [S]. 2010: 1045.
[6]
WHO. WHO guidelines on the quality,safety,and efficacy of biotherapeutic products prepared by recombinant DNA technology[EB/OL].http://www. Who. int/biologicals /WHO_rDNA_2nd_public_consultation_28_June_2013. pdf;2013.
[7]
ICH. Quality guidelines.Quality of biotechnological products Q5A, viral safety evaluation of biotechnology products derived from cell lines of human or animal origin[EB/OL]. http://www. ich. org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1 /Step4/Q5A_R1_Guideline. Pdf. 23/09/1999.
[8]
ICH Quality guidelines. Quality of biotechnological products Q5B, quality of biothechnological products: analysis of the expression construct in cells used for production of r-DNA derived protein products[EB/OL]. http://www. ich. org/fileadmin/Public_Web_Site/ICH _ Products/Guidelines/Quality/Q5B/Step4/Q5B_Guideline. pdf. 30/11/1995.
[9]
PEI D N,GUO Y,LI Y H, et al. Sampling results and quality assessment of recombinant human interferon��2a injections[J]. China Pharm (�й�ҩ��),2015,18(1):52-55
[10]
EP [S]. 8th ed. 2013. 2504
[11]
YU L, RAO C M, SHI X C, et al. A novel bioassay for the activity determination of therapeutic human brain natriuretic peptide (BNP)[J]. PLoS One,2012, 7(11): 1-8.
[12]
YANG Y S,ZHOU Y, YU L, et al. A novel reporter gene assay for recombinant human erythropoietin(rHuEPO) pharmaceutical products[J]. J Pharm Biomed Anal,2014,100 (8):316-321.
[13]
RAO C M, ZHANG Y, HAN C M, et al. Peptide mapping analysis of recombinant human Interleukin-11 by tryptic digestion[J]. Acta Pharm Sin(ҩѧѧ��), 2000, 35(5): 378-380.
[14]
TAO L, PEI D N, HAN C M, et al. Characterization and comparison of interferon referencestandards using UPLC-MS[J]. Acta Pharm Sin(ҩѧѧ��), 2015, 50(1): 75-80.
[15]
FAN W H,TAO L,LI X, et al. Development of standardized methods for quality control of humanizedmonoclonal antibody HcHAb18 and structure confirmation ofits reference substance for physicochemical analysis[J]. Chin New Drugs J(�й���ҩ��־),2014,23(20):2360-2365.
[16]
TAO L, DING Y X, GUO Y, et al. Characterization of the primary structure of TNK-tissueplasminogen activator using LC-MS[J]. Acta Pharm Sin (ҩѧѧ��),2013, 48(6): 896-900.
2015, Vol. 50 
